Franklin Resources Inc Savara Inc Transaction History

Franklin Resources Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $2,510 - $3,470	1,846 Added 1.01%	183,880 $285,000
Q2 2022 Aug 11, 2022	SELL	$1.1 - $1.58 $68,052 - $97,748	-61,866 Reduced 25.37%	182,034 $277,000
Q1 2022 May 13, 2022	BUY	$1.05 - $1.36 $1,054 - $1,365	1,004 Added 0.41%	243,900 $320,000
Q4 2021 Feb 11, 2022	SELL	$1.04 - $1.34 $628 - $809	-604 Reduced 0.25%	242,896 $301,000
Q3 2021 Nov 12, 2021	BUY	$1.18 - $1.64 $287,330 - $399,340	243,500 New	243,500 $336,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

Stay updated on Franklin Resources Inc with notifications on news.